JP2019505533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505533A5 JP2019505533A5 JP2018540799A JP2018540799A JP2019505533A5 JP 2019505533 A5 JP2019505533 A5 JP 2019505533A5 JP 2018540799 A JP2018540799 A JP 2018540799A JP 2018540799 A JP2018540799 A JP 2018540799A JP 2019505533 A5 JP2019505533 A5 JP 2019505533A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal form
- ray powder
- crystalline
- diffraction pattern
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 238000002425 crystallisation Methods 0.000 claims 4
- 230000008025 crystallization Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 claims 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082029.8 | 2016-02-05 | ||
| CN201610082029.8A CN107043379A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| PCT/CN2017/072891 WO2017133684A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的晶型a、其制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505533A JP2019505533A (ja) | 2019-02-28 |
| JP2019505533A5 true JP2019505533A5 (enExample) | 2020-02-27 |
| JP6889171B2 JP6889171B2 (ja) | 2021-06-18 |
Family
ID=59499348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540799A Active JP6889171B2 (ja) | 2016-02-05 | 2017-02-04 | Ｔｌｒ７アゴニスト結晶形ａ、その調製方法及び使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10442811B2 (enExample) |
| EP (1) | EP3412672B1 (enExample) |
| JP (1) | JP6889171B2 (enExample) |
| KR (1) | KR102393280B1 (enExample) |
| CN (2) | CN107043379A (enExample) |
| AR (1) | AR107548A1 (enExample) |
| AU (1) | AU2017215801B2 (enExample) |
| CA (1) | CA3013518C (enExample) |
| CL (1) | CL2018002092A1 (enExample) |
| DK (1) | DK3412672T3 (enExample) |
| EA (1) | EA035951B1 (enExample) |
| ES (1) | ES2830443T3 (enExample) |
| HR (1) | HRP20201644T1 (enExample) |
| HU (1) | HUE051399T2 (enExample) |
| IL (1) | IL260968B (enExample) |
| LT (1) | LT3412672T (enExample) |
| MX (1) | MX374297B (enExample) |
| NZ (1) | NZ744884A (enExample) |
| PH (1) | PH12018501643A1 (enExample) |
| PL (1) | PL3412672T3 (enExample) |
| PT (1) | PT3412672T (enExample) |
| SG (1) | SG11201806683UA (enExample) |
| SI (1) | SI3412672T1 (enExample) |
| TW (1) | TWI754629B (enExample) |
| UA (1) | UA121161C2 (enExample) |
| WO (1) | WO2017133684A1 (enExample) |
| ZA (1) | ZA201805186B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108430515B (zh) | 2015-10-29 | 2021-11-12 | 诺华股份有限公司 | 包含toll-样受体激动剂的抗体缀合物 |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| WO2019223788A1 (zh) * | 2018-05-25 | 2019-11-28 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| US12263172B2 (en) | 2019-03-15 | 2025-04-01 | Chia Tai Tianqing Pharmeceutical Group Co., Ltd. | Toll-like receptor agonists for use in the treatment of hepatitis b |
| WO2020216274A1 (zh) * | 2019-04-23 | 2020-10-29 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的固体药物组合物 |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| CA2620182A1 (en) * | 2005-08-22 | 2007-03-01 | Dennis A. Carson | Tlr agonists |
| WO2010077613A1 (en) | 2008-12-09 | 2010-07-08 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| WO2012106522A2 (en) * | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| WO2013103967A1 (en) | 2012-01-05 | 2013-07-11 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| NZ705589A (en) * | 2012-10-10 | 2019-05-31 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| KR20150085081A (ko) * | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| SMT201700378T1 (it) * | 2012-11-20 | 2017-09-07 | Glaxosmithkline Llc | Nuovi composti |
| WO2015168269A1 (en) | 2014-05-01 | 2015-11-05 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
| LT3190113T (lt) | 2014-08-15 | 2021-08-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
-
2016
- 2016-02-05 CN CN201610082029.8A patent/CN107043379A/zh active Pending
-
2017
- 2017-02-03 TW TW106103695A patent/TWI754629B/zh active
- 2017-02-04 JP JP2018540799A patent/JP6889171B2/ja active Active
- 2017-02-04 PL PL17747004T patent/PL3412672T3/pl unknown
- 2017-02-04 PT PT177470044T patent/PT3412672T/pt unknown
- 2017-02-04 DK DK17747004.4T patent/DK3412672T3/da active
- 2017-02-04 CA CA3013518A patent/CA3013518C/en active Active
- 2017-02-04 EP EP17747004.4A patent/EP3412672B1/en active Active
- 2017-02-04 ES ES17747004T patent/ES2830443T3/es active Active
- 2017-02-04 SI SI201730461T patent/SI3412672T1/sl unknown
- 2017-02-04 AU AU2017215801A patent/AU2017215801B2/en active Active
- 2017-02-04 SG SG11201806683UA patent/SG11201806683UA/en unknown
- 2017-02-04 HR HRP20201644TT patent/HRP20201644T1/hr unknown
- 2017-02-04 EA EA201891768A patent/EA035951B1/ru not_active IP Right Cessation
- 2017-02-04 MX MX2018009501A patent/MX374297B/es active IP Right Grant
- 2017-02-04 HU HUE17747004A patent/HUE051399T2/hu unknown
- 2017-02-04 NZ NZ744884A patent/NZ744884A/en unknown
- 2017-02-04 UA UAA201809129A patent/UA121161C2/uk unknown
- 2017-02-04 US US16/075,297 patent/US10442811B2/en active Active
- 2017-02-04 CN CN201780009747.5A patent/CN108602831B9/zh active Active
- 2017-02-04 KR KR1020187024627A patent/KR102393280B1/ko active Active
- 2017-02-04 LT LTEP17747004.4T patent/LT3412672T/lt unknown
- 2017-02-04 WO PCT/CN2017/072891 patent/WO2017133684A1/zh not_active Ceased
- 2017-02-06 AR ARP170100297A patent/AR107548A1/es not_active Application Discontinuation
-
2018
- 2018-08-01 ZA ZA2018/05186A patent/ZA201805186B/en unknown
- 2018-08-02 IL IL260968A patent/IL260968B/en unknown
- 2018-08-02 PH PH12018501643A patent/PH12018501643A1/en unknown
- 2018-08-03 CL CL2018002092A patent/CL2018002092A1/es unknown
-
2019
- 2019-09-25 US US16/582,575 patent/US10947245B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505533A5 (enExample) | ||
| JP2019504103A5 (enExample) | ||
| JP2019505532A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| JP2015522644A5 (enExample) | ||
| JP2014501282A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2017505329A5 (enExample) | ||
| JP2011512396A (ja) | 新規な多形およびその調製方法 | |
| JP2018520147A5 (enExample) | ||
| WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
| JP2019516749A5 (enExample) | ||
| JP2017210488A5 (enExample) | ||
| JP2016510768A5 (enExample) | ||
| CN107698574B (zh) | 一种高纯度阿瑞匹坦的精制制备工艺 | |
| JP2022060192A5 (enExample) | ||
| CN112771052A (zh) | 促性腺素释放激素拮抗剂的晶型及其制备方法和用途 | |
| JP2018522945A5 (enExample) | ||
| JP2015531354A5 (enExample) | ||
| TW201217346A (en) | Process for preparing the crystalline form II of febuxostat | |
| CN106604916A (zh) | 钾离子竞争性酸阻滞剂的晶型及其制备方法 | |
| CN107033094A (zh) | 一种药物共晶的晶型及其制备方法和组合物 | |
| JP2010502682A5 (enExample) | ||
| JP2018509421A5 (enExample) |